Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Tribenzor Proves Effective Across Subgroups

By Drug Discovery Trends Editor | May 24, 2011

Data evaluating the long-term efficacy and safety of Tribenzor (olmesartan medoxomil, amlodipine besylate, plus hydrochlorothiazide) in patients with hypertension aged 65 years and older showed that the triple therapy was well-tolerated and effective in maintaining the blood pressure reductions, regardless of age, race, or diabetes status. 

The pre-specified subgroup analysis results, presented at the American Society of Hypertension, Inc. (ASH) 26th Annual Scientific Meeting and Exposition, found that a similar percentage of patients treated with the triple therapy achieved BP goal in both age groups. The triple therapy was well-tolerated in both age groups and most adverse events (AE) were mild or moderate in severity.

“Older patients generally have a more difficult time achieving recommended blood pressure levels and as a result, their hypertension often remains uncontrolled,” said Suzanne Oparil, MD, professor of medicine and physiology and biophysics at the University of Alabama School of Medicine. “However this analysis shows that long-term blood pressure control can be achieved safely and effectively across all studied dosing strengths with a triple combination therapy regardless of age. This is important given the fact that more than 64% of men and 75% of women 70 years or older have high blood pressure.”

Release Date: May 23, 2011
Source: Daiichi Sankyo Group  


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE